Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report

Merve Şimşek Dilli; Fettah Acıbucu; Zübeyde Şebnem Aktaran; Şekure Demet Küçük

doi:10.18678/dtfd.1899708

Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report

Abstract

Silent corticotroph pituitary neuroendocrine tumors are a rare subtype of non-functioning pituitary neuroendocrine tumors that lack the clinical and biochemical manifestations of Cushing disease. These tumors are associated with an aggressive clinical course because of a tendency for rapid progression and invasive growth, as well as a high recurrence rate. We present a 41-year-old woman without Cushingoid symptoms who presented with headache, bitemporal hemianopia, and diplopia. MRI revealed a mass extending into the suprasellar region, measuring approximately 2 × 4 cm, with internal necrotic areas and post-contrast enhancement. Following transsphenoidal resection, immunohistochemical staining demonstrated positivity for adrenocorticotropic hormone, confirming the diagnosis of a silent corticotroph pituitary neuroendocrine tumor. This case highlights the importance of recognizing silent corticotroph pituitary neuroendocrine tumors, the treatment approach, and long-term follow-up.

Keywords

References

Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, et al. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery. 2012;71(2):296-303; discussion 304. doi:10.1227/NEU.0b013e318257c1f0.
Cooper O. Silent corticotroph adenomas. Pituitary. 2015;18(2):225-31. doi:10.1007/s11102-014-0624-3.
Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022;33(1):6-26. doi:10.1007/s12022-022-09703-7.
Sumislawski P, Huckhagel T, Krajewski KL, Aberle J, Saeger W, Flitsch J, et al. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study. Sci Rep. 2023;13(1):2468. doi:10.1038/s41598-023-29628-3.
Jiang S, Zhu J, Feng M, Yao Y, Deng K, Xing B, et al. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary. 2021;24(4):564-73. doi:10.1007/s11102-021-01133-8.
Goyal-Honavar A, Sarkar S, Asha HS, Kapoor N, Balakrishnan R, Vanjare H, et al. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors. Acta Neurochir (Wien). 2021;163(11):3143-54. doi:10.1007/s00701-021-04911-2.
Himstead AS, Wells AC, Kurtz JS, Moldenhauer MR, Davies JL, Fote GM, et al. Silent corticotroph adenomas demonstrate predilection for sphenoid sinus, cavernous sinus, and clival invasion compared with other subtypes. World Neurosurg. 2024;191:e41-7. doi:10.1016/j.wneu.2024.08.027.
Jiang S, Chen X, Wu Y, Wang R, Bao X. An update on silent corticotroph adenomas: diagnosis, mechanisms, clinical features, and management. Cancers (Basel). 2021;13(23):6134. doi:10.3390/cancers13236134.

Vitale G, Tortora F, Baldelli R, Cocchiara F, Paragliola RM, Sbardella E, et al. Pituitary magnetic resonance imaging in Cushing's disease. Endocrine. 2017;55(3):691-6. doi:10.1007/s12020-016-1038-y.
Righi A, Faustini-Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine. 2017;56(2):286-97. doi:10.1007/s12020-016-1028-0.
Langlois F, Lim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, et al. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. 2018;21(1):32-40. doi:10.1007/s11102-017-0844-4.
Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-35. doi:10.1007/s00401-017-1769-8.
Yamamoto M, Nakao T, Ogawa W, Fukuoka H. Aggressive Cushing's disease: molecular pathology and its therapeutic approach. Front Endocrinol (Lausanne). 2021;12:650791. doi:10.3389/fendo.2021.650791.
Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26(4):349-55. doi:10.1007/s12022-015-9398-z.
Demarchi G, Perrone S, Esper Romero G, De Bonis C, Casasco JP, Sevlever G, et al. Case report: progression of a silent corticotroph tumor to an aggressive secreting corticotroph tumor, treated by temozolomide. Changes in the clinic, the pathology, and the β-catenin and α-SMA expression. Front Endocrinol (Lausanne). 2022;13:870172. doi:10.3389/fendo.2022.870172.
Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17(11):671-84. doi:10.1038/s41574-021-00550-w.
Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery. 2013;73(1):8-17; discussion 17-8. doi:10.1227/01.neu.0000429858.96652.1e.

Details

Primary Language

English

Subjects

Endocrinology

Journal Section

Case Report

Authors

Merve Şimşek Dilli ^*
0009-0000-0493-946X
Türkiye

Fettah Acıbucu
0000-0002-2252-2112
Türkiye

Zübeyde Şebnem Aktaran
0000-0002-6978-5155
Türkiye

Şekure Demet Küçük
0000-0003-3175-1256
Türkiye

Publication Date

August 21, 2026

Submission Date

February 28, 2026

Acceptance Date

August 10, 2026

Published in Issue

Year 2026 Volume: 28 Number: 2

DOI

https://doi.org/10.18678/dtfd.1899708

IZ

https://izlik.org/JA99CA68LR

Cite

RIS / Bibtex

APA

Şimşek Dilli, M., Acıbucu, F., Aktaran, Z. Ş., & Küçük, Ş. D. (2026). Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Duzce Medical Journal, 28(2), 252-256. https://doi.org/10.18678/dtfd.1899708

AMA

1.Şimşek Dilli M, Acıbucu F, Aktaran ZŞ, Küçük ŞD. Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Duzce Med J. 2026;28(2):252-256. doi:10.18678/dtfd.1899708

Chicago

Şimşek Dilli, Merve, Fettah Acıbucu, Zübeyde Şebnem Aktaran, and Şekure Demet Küçük. 2026. “Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report”. Duzce Medical Journal 28 (2): 252-56. https://doi.org/10.18678/dtfd.1899708.

EndNote

Şimşek Dilli M, Acıbucu F, Aktaran ZŞ, Küçük ŞD (August 1, 2026) Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Duzce Medical Journal 28 2 252–256.

IEEE

[1]M. Şimşek Dilli, F. Acıbucu, Z. Ş. Aktaran, and Ş. D. Küçük, “Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report”, Duzce Med J, vol. 28, no. 2, pp. 252–256, Aug. 2026, doi: 10.18678/dtfd.1899708.

ISNAD

Şimşek Dilli, Merve - Acıbucu, Fettah - Aktaran, Zübeyde Şebnem - Küçük, Şekure Demet. “Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report”. Duzce Medical Journal 28/2 (August 1, 2026): 252-256. https://doi.org/10.18678/dtfd.1899708.

JAMA

1.Şimşek Dilli M, Acıbucu F, Aktaran ZŞ, Küçük ŞD. Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Duzce Med J. 2026;28:252–256.

MLA

Şimşek Dilli, Merve, et al. “Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report”. Duzce Medical Journal, vol. 28, no. 2, Aug. 2026, pp. 252-6, doi:10.18678/dtfd.1899708.

Vancouver

1.Merve Şimşek Dilli, Fettah Acıbucu, Zübeyde Şebnem Aktaran, Şekure Demet Küçük. Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Duzce Med J. 2026 Aug. 1;28(2):252-6. doi:10.18678/dtfd.1899708